{
  "schemaVersion": "2.1",
  "datasetVersion": "2026-09-11.1",
  "generatedAt": "2026-09-11",
  "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.",
  "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.",
  "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.",
  "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.",
  "changeLogPath": "/corrections#correction-ledger",
  "contactPath": "/corrections",
  "dataset": "peptide-evidence-checker-record",
  "canonicalPath": "/peptides/teduglutide",
  "canonicalUrl": "https://thepeptidefield.com/peptides/teduglutide",
  "record": {
    "slug": "teduglutide",
    "name": "Teduglutide",
    "aliases": [
      "Gattex",
      "ALX-0600",
      "GLP-2 analogue"
    ],
    "className": "Glucagon-like peptide-2 analogue",
    "family": "Gut and intestinal peptide medicines",
    "sequenceLabel": "33 amino acids · DPP-4-resistant GLP-2 analogue",
    "tier": "Established",
    "evidenceContext": "Approved human outcomes",
    "statusLine": "Teduglutide is a 33-amino-acid GLP-2 analog. In the United States, Gattex (teduglutide) is FDA-approved for people age 1 and older who have short bowel syndrome and depend on fluids or nutrition given through a vein.",
    "productContext": "Gattex evidence applies to a specific monitored prescription product. Gattex is a labeled prescription product used with structured monitoring. Its evidence does not establish general gut healing or equivalence for compounded GLP-2 analogues.",
    "approvedProducts": [
      "Gattex"
    ],
    "productRecords": [
      {
        "name": "Gattex",
        "formulation": "Powder and diluent for injection",
        "route": "Subcutaneous",
        "indicationScope": "Short bowel syndrome with parenteral-support dependence in the adult and pediatric populations defined in the label.",
        "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf",
        "labelRevision": "2025 label"
      }
    ],
    "indications": [
      "Short bowel syndrome with dependence on parenteral support in labeled adults and children"
    ],
    "profile": {
      "humanOutcomes": {
        "level": "Strong",
        "note": "Randomized trials support reduction in parenteral-support requirements for short bowel syndrome."
      },
      "humanPharmacology": {
        "level": "Strong",
        "note": "Intestinal absorption, exposure, and product effects are characterized in the label and trials."
      },
      "safetyKnowledge": {
        "level": "Strong",
        "note": "The label addresses neoplastic growth, obstruction, biliary and pancreatic disease, and fluid imbalance."
      },
      "productCertainty": {
        "level": "Strong",
        "note": "High for authentic Gattex used within its monitoring program."
      }
    },
    "oneLine": "An established medicine that can reduce support given through a vein in short bowel syndrome. It needs intensive product-specific monitoring.",
    "reviewedAt": "July 23, 2026",
    "reviewedAtISO": "2026-07-23",
    "reviewHistory": [
      {
        "date": "2026-07-23",
        "note": "Initial brief based on the 2025 Gattex label, randomized trial, and orphan-drug record."
      }
    ],
    "whatItIs": "Teduglutide is a changed version of GLP-2, a body signal that affects intestinal absorption. Gattex is approved for people with short bowel syndrome who depend on parenteral support, such as fluids or nutrition given through a vein.",
    "whatWeKnow": "Randomized trials found that some participants needed less fluid or nutrition through a vein. The product label defines required screening and ongoing monitoring.",
    "whatWeDoNotKnow": "The evidence does not establish broad treatment of leaky gut, inflammatory symptoms, wellness, or mucosal repair in people without the labeled syndrome.",
    "antiDoping": null,
    "safetyBoundary": "This monitored prescription therapy has serious risks, including possible acceleration of neoplastic growth. No dosing, reconstitution, or self-treatment guidance is provided.",
    "relatedSlugs": [
      "liraglutide",
      "semaglutide"
    ],
    "claims": [
      {
        "claim": "“Teduglutide can reduce parenteral-support needs in short bowel syndrome.”",
        "verdict": "Supported with scope",
        "explanation": "Controlled trials and the Gattex label support this outcome in dependent short-bowel-syndrome populations.",
        "category": "Clinical outcomes",
        "evidenceBasis": "Randomized human outcomes",
        "scope": "Adults and labeled pediatric populations with short bowel syndrome dependent on parenteral support.",
        "sourceUrls": [
          "https://pubmed.ncbi.nlm.nih.gov/22982184/",
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf"
        ]
      },
      {
        "claim": "“Teduglutide is a general gut-healing peptide.”",
        "verdict": "Misleading",
        "explanation": "The approved indication and outcome are specific to short bowel syndrome with parenteral-support dependence.",
        "category": "Clinical outcomes",
        "evidenceBasis": "Regulatory or product record",
        "scope": "The current Gattex indication.",
        "sourceUrls": [
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf"
        ]
      },
      {
        "claim": "“Because teduglutide promotes intestinal growth, it is low risk.”",
        "verdict": "Misleading",
        "explanation": "The same biological activity underlies important warnings, including potential acceleration of neoplastic growth.",
        "category": "Safety",
        "evidenceBasis": "Regulatory or product record",
        "scope": "Approved Gattex use with required screening and monitoring.",
        "sourceUrls": [
          "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf"
        ]
      }
    ],
    "sources": [
      {
        "label": "GATTEX (teduglutide) prescribing information",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203441s024lbl.pdf",
        "kind": "Drug label",
        "year": 2025,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "Teduglutide reduces parenteral support in short bowel syndrome",
        "publisher": "PubMed · Gastroenterology",
        "url": "https://pubmed.ncbi.nlm.nih.gov/22982184/",
        "kind": "Randomized trial",
        "year": 2012,
        "accessedAt": "2026-07-23"
      },
      {
        "label": "Teduglutide orphan drug designation and approval",
        "publisher": "U.S. Food and Drug Administration",
        "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=126999",
        "kind": "Regulatory",
        "year": 2019,
        "accessedAt": "2026-07-23"
      }
    ],
    "antiDopingReview": {
      "status": "Not assessed",
      "detail": "This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.",
      "sourceUrl": null,
      "reviewedAtISO": "2026-07-23"
    }
  }
}